2013- 2014 Publications

2014

  1. Palumbo A, Bringhen S, Kumar SK, Lupparelli G, Usmani S, Waage A, Larocca A, van der Holt B, Musto P, Offidani M, Petrucci MT, Evangelista A, Zweegman S, Nooka AK, Spencer A, Dimopoulos MA, Hajek R, Cavo M, Richardson P, Lonial S, Ciccone G, Boccadoro M, Anderson K, Barlogie B, Sonneveld P, McCarthy PL. Lancet Oncol. 2014 Feb 10. pii: S1470-2045(13)70609-0. doi: 10.1016/S1470-2045(13)70609-0. [Epub ahead of print] Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.
  2. Liu YC, Reddi HV, Waheed S, Alapat D, Highsmith WE, Edmondson RD, Barlogie B, van Rhee F.  Amyloid. 2014 Feb 11. [Epub ahead of print] No abstract available.A compound T60A and V122I heterozygosity in the transthyretin gene causing early onset severe cardiac amyloidosis.
  3. Sawyer JR, Tian E, Heuck CJ, Epstein J, Johann DJ, Swanson CM, Lukacs JL, Johnson M, Binz R, Boast A, Sammartino G, Usmani S, Zangari M, Waheed S, van Rhee F, Barlogie B.Blood. 2014 Feb 4. [Epub ahead of print] Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease.
  4. Zhao S, Choi M, Heuck C, Mane S, Barlogie B, Lifton RP, Dhodapkar MV.  Leukemia. 2014 Feb 5. doi: 10.1038/leu.2014.59. [Epub ahead of print] No abstract available.Serial exome analysis of disease progression in premalignant gammopathies.
  5. Raina S, Pant S, Vallurupalli S, Jambhekar K, Pandey T, Grazziutti M, Barlogie B, Dai Y, Deshmukh A, Mehta JL. Int J Cardiol. 2014 Jan 10. pii: S0167-5273(14)00124-7. doi: 10.1016/j.ijcard.2013.12.249. [Epub ahead of print] No abstract available.  Can autologous bone marrow transplantation improve systolic function in patients with multiple myeloma related cardiac amyloidosis?

2013

  1. Abdallah AO, Atrash S, Shahid Z, Jameel M, Grazziutti M, Apewokin S, Kumar NS, Restrepo A, Waheed S, Van Rhee F, Heuck CJ, Johann D Jr, Barlogie B, Usmani SZ. Clin Lymphoma Myeloma Leuk. 2013 Nov 16. pii: S2152-2650(13)00469-2. doi: 10.1016/j.clml.2013.11.004. [Epub ahead of print] Patterns of Central Nervous System Involvement in Relapsed and Refractory Multiple Myeloma.
  2. Abuabdou A, Rosenbaum ER, Usmani SZ, Barlogie B, Cottler-Fox M.J Clin Apher. 2013 Dec 18. doi: 10.1002/jca.21313. [Epub ahead of print] Analysis of CD34+ cell collection using two mobilization regimens for newly diagnosed multiple myeloma patients reveals the separate impact of mobilization and collection variables.
  3. Dhodapkar MV, Sexton R, Waheed S, Usmani S, Papanikolaou X, Nair B, Petty N, Shaughnessy JD Jr, Hoering A, Crowley J, Orlowski RZ, Barlogie B.Blood. 2013 Nov 6. [Epub ahead of print]PMID:24144643[PubMed - as supplied by publisher] Clinical, genomic and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120).

  4. Schuster SR, Kortuem KM, Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Ahmann G, Kumar S, Rajkumar SV, Mikhael J, Laplant B, Champion MD, Laumann K, Barlogie B, Fonseca R, Bergsagel PL, Lacy M, Stewart AK. Leuk Res. 2014 Jan;38(1):23-8. doi: 10.1016/j.leukres.2013.08.015. Epub 2013 Sep 5.PMID:24129344[PubMed - in process] The clinical significance of cereblon expression in multiple myeloma.

  5. Hu B, Chen Y, Usmani SZ, Ye S, Qiang W, Papanikolaou X, Heuck CJ, Yaccoby S, Williams BO, Van Rhee F, Barlogie B, Epstein J, Qiang YW. PLoS One. 2013 Sep 16;8(9):e74191. doi: 10.1371/journal.pone.0074191. PMID:24066119[PubMed - in process] Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma.

  6. Papanikolaou X, Rosenbaum ER, Tyler LN, Sawyer J, Heuck CJ, Barlogie B, Cottler-Fox M.Leukemia. 2013 Jul 15. doi: 10.1038/leu.2013.214. [Epub ahead of print]PMID: 23852547 [PubMed - as supplied by publisher]Hematopoietic progenitor cell collection after autologous transplant for multiple myeloma: low platelet count predicts for poor collection and sole use of resulting graft enhances risk of myelodysplasia.
  7. Sanchorawala V, Hoering A, Seldin DC, Finn KT, Fennessey SA, Sexton R, Mattar B, Safah HF, Holmberg LA, Dean RM, Orlowski RZ, Barlogie B.Bone Marrow Transplant. 2013 Jul 15. doi: 10.1038/bmt.2013.98. [Epub ahead of print]PMID: 23852321 [PubMed - as supplied by publisher] Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115.
  8. Abdallah AO, Atrash S, Muzaffar J, Abdallah M, Kumar M, Van Rhee F, Barlogie B.Clin Lymphoma Myeloma Leuk. 2013 Aug;13(4):502-6. doi: 10.1016/j.clml.2013.03.002. Epub 2013 Jun 5. No abstract available. PMID: 23747080 [PubMed - in process]Successful Treatment of Bing-Neel Syndrome Using Intrathecal Chemotherapy and Systemic Combination Chemotherapy Followed by BEAM Auto-Transplant: A Case Report and Review of Literature.
  9. Erdem E, Samant R, Malak SF, Culp WC, Brown A, Peterson L, Lensing S, Barlogie B.Leukemia. 2013 Jun 3. doi: 10.1038/leu.2013.162. [Epub ahead of print] No abstract available. PMID: 23728152 [PubMed - as supplied by publisher]Vertebral Augmentation in the Treatment of Pathologic Compression Fractures in 792 Patients with Multiple Myeloma.
  10. Papanikolaou X, Szymonifka J, Rosenthal A, Heuck CJ, Mitchell A, Johann D Jr, Keller J, Waheed S, Usmani SZ, Van Rhee F, Bailey C, Petty N, Hoering A, Crowley J, Barlogie B.Haematologica. 2013 Jul;98(7):1147-53. doi: 10.3324/haematol.2013.085183. Epub 2013 May 28. PMID: 23716540 [PubMed - in process] Free PMC Article Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma.
  11. Gatt ME, Takada K, Mani M, Lerner M, Pick M, Hideshima T, Carrasco DE, Protopopov A, Ivanova E, Sangfelt O, Grandér D, Barlogie B, Shaughnessy JD Jr, Anderson KC, Carrasco DR.Br J Haematol. 2013 Jul;162(2):210-20. doi: 10.1111/bjh.12365. Epub 2013 May 7.PMID: 23647456 [PubMed - in process]TRIM13 (RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activity.
  12. Usmani SZ, Sawyer J, Rosenthal A, Cottler-Fox M, Epstein J, Yaccoby S, Sexton R, Hoering A, Singh Z, Heuck CJ, Waheed S, Chauhan N, Johann D, Abdallah AO, Muzaffar J, Petty N, Bailey C, Crowley J, van Rhee F, Barlogie B.Blood. 2013 Jun 6;121(23):4753-7. doi: 10.1182/blood-2012-11-466961. Epub 2013 Apr 19.Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.PMID: 23603914 [PubMed - indexed for MEDLINE]
  13. Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S, Borghaei H, Jagannath S, Sokol L, Usmani SZ, van de Velde H, Qin X, Puchalski TA, Hall B, Reddy M, Qi M, van Rhee F.Clin Cancer Res. 2013 Jul 1;19(13):3659-70. doi: 10.1158/1078-0432.CCR-12-3349. Epub 2013 May 9.PMID: 23659971 [PubMed - in process]A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.
  14. Fajgenbaum D, Rosenbach M, van Rhee F, Nasir A, Reutter J.JAMA Dermatol. 2013 Feb;149(2):204-8. doi: 10.1001/jamadermatol.2013.1552.PMID: 23426475 [PubMed - indexed for MEDLINE]Eruptive cherry hemangiomatosis associated with multicentric Castleman disease: a case report and diagnostic clue.
  15. Waheed S, Mitchell A, Usmani S, Epstein J, Yaccoby S, Nair B, van Hemert R, Angtuaco E, Brown T, Bartel T, McDonald J, Anaissie E, van Rhee F, Crowley J, Barlogie B.Haematologica. 2013 Jan;98(1):71-8. doi: 10.3324/haematol.2012.066555. Epub 2012 Jun 24.PMID: 22733020 [PubMed - in process] Free PMC ArticleStandard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data.
  16. Bakhous A, Zhu H, Waheed S.Br J Haematol. 2013 Aug 9. doi: 10.1111/bjh.12527. [Epub ahead of print] No abstract available. PMID: 23930696 [PubMed - as supplied by publisher]Waldeström macroglobulinaemia relapsing with focal bone disease and achieving major response with single-agent zoledronic acid.
  17. Avet-Loiseau H, Durie BG, Cavo M, Attal M, Gutierrez N, Haessler J, Goldschmidt H, Hajek R, Lee JH, Sezer O, Barlogie B, Crowley J, Fonseca R, Testoni N, Ross F, Rajkumar SV, Sonneveld P, Lahuerta J, Moreau P, Morgan G; International Myeloma Working Group.Leukemia. 2013 Mar;27(3):711-7. doi: 10.1038/leu.2012.282. Epub 2012 Oct 3.PMID: 23032723 [PubMed - indexed for MEDLINE]Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project.
  18. Usmani SZ, Mitchell A, Waheed S, Crowley J, Hoering A, Petty N, Brown T, Bartel T, Anaissie E, van Rhee F, Barlogie B.Blood. 2013 Jan 10. [Epub ahead of print]PMID: 23305732Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with Total Therapy 3.
  19. Venkateshaiah SU, Khan S, Ling W, Bam R, Li X, van Rhee F, Usmani S, Barlogie B, Epstein J, Yaccoby S.Exp Hematol. 2013 Feb 19. doi:pii: S0301-472X(13)00056-8. 10.1016/j.exphem.2013.02.008. [Epub ahead of print]PMID: 23435312NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity.http://www.ncbi.nlm.nih.gov/pubmed/23435312
  20. Stone K, Woods E, Szmania SM, Stephens OW, Garg TK, Barlogie B, Shaughnessy JD Jr, Hall B, Reddy M, Hoering A, Hansen E, van Rhee F.PLoS One. 2013;8(1):e54610. doi: 10.1371/journal.pone.0054610. Epub 2013 Jan 23.PMID: 23372742http://www.ncbi.nlm.nih.gov/pubmed/23372742 Interleukin-6 Receptor Polymorphism Is Prevalent in HIV-negative Castleman Disease and Is Associated with Increased Soluble Interleukin-6 Receptor Levels.
  21. Bam R, Ling W, Khan S, Pennisi A, Venkateshaiah SU, Li X, van Rhee F, Usmani S, Barlogie B, Shaughnessy J, Epstein J, Yaccoby S.Am J Hematol. 2013 Mar 2. doi: 10.1002/ajh.23433. [Epub ahead of print]PMID: 23456977Role of Bruton’s tyrosine kinase (BTK) in myeloma cell migration and induction of bone disease.